Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
株式のランク #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
株価
$19.30
最終同期: 2023-12-26
時価総額
$72.77M
変化(1日)
6.22%
変化(1年)
0.00%
US
取引 Aeglea BioTherapeutics, Inc. (AGLE)

カテゴリー

Aeglea BioTherapeutics, Inc.(AGLE)の株式分割履歴
Aeglea BioTherapeutics, Inc.株(シンボル:AGLE)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 22, 2026に行われました。
Aug 22, 2026より前に購入されたAGLE株は、現在0AGLE株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH